INTRODUCTION
============

Tuberculosis (TB) is one of the important leading causes of death in humans, and it remains a serious public health obstacle in the developing countries. It is estimated that 1.4 million people annually die due to this treatable disease and 9 million incident cases of TB are estimated globally.[@B1] According to the report, Mycobacterium tuberculosis (MTB) infect about one-third of population; however, only approximately one-tenth of those infected will ever develop active TB, which indicate that MTB infection is the result of the interplay between host genetic susceptibility and environmental factors.[@B2]

Interleukin-10 (IL-10) is a multifunctional regulatory cytokine of inflammatory responses. Increasing numbers of studies[@B3] have demonstrated that IL-10 acts as a general inhibitor of proliferative and cytokine responses of both T helper (Th) 1 and Th2 cells *in vitro* and *in vivo*. IL-10 plays an anti-inflammatory action by suppressing the production of cytokines such as IL-1α, IL-1β, IL-6, IL-8, IL-12, and tumor necrosis factor-alpha in activated macrophage and interferon gamma in T cells. The *IL-10* gene is located on chromosome 1 (1q31-1q32) with five exons. The promoter region of *IL-10* gene has been found to be highly polymorphic and its many polymorphisms have been identified.[@B4] In the past few years, the impact of three common polymorphisms in the promoter of *IL-10* gene -592A/C, -1082 G/A, and -819C/T on susceptibility to TB have been reported, and results suggested that these polymorphisms contribute to the risk of TB by affecting IL-10 transcription level, but the findings are controversial.

The human interleukin-6 (*IL-6*) gene is located at 7p21-24 locus with an upstream promoter containing 303 bp. IL-6 is a pleiotropic cytokine, secreted as a T-cell derived factor by a variety of cell types including lymphocytes, monocytes, and endothelial cells. It has endocrine as well as paracrine and autocrine actions implicated in several physiologic and pathologic processes including immunity and inflammation, activation of fibroblasts, mast cells, endothelial cells, monocytes, and keratinocytes.[@B5] Furthermore, the genetic polymorphism in the *IL-6* promoter (-174G/C) that influences its transcription rate might play a crucial role in host immunity and susceptibility to TB.[@B6]

A relatively large number of studies found the association between *IL-10* and *IL-6* polymorphisms and TB risk, however, the results have been inconsistent and inconclusive due to limited sample sizes and different study populations. Therefore, we performed this meta-analysis on all eligible case-control studies to estimate the effect of polymorphisms in the *IL-10* and *IL-6* genes on the risk of TB.

MATERIALS AND METHODS
=====================

Identification of relevant studies
----------------------------------

Relevant publications were identified with a literature search using terms \"*IL-10*\" or \"Interleukin-10\" or \"*IL-6*\" or \"Interleukin-6\" and \"tuberculosis\" or \"TB\" or \"TB infection\" or \"TB disease\" and \"polymorphism\" or \"genotype\" or \"variant\" in the PubMed, Medline, Embase, Web of Science, Elsevier Science Direct and Cochrane Library database (the last search update was 1 February 2014), and the search was limited to English-language journals. Additional studies were identified by a manual search of the references of original studies. The following criteria were used for inclusion in the analysis: 1) a case-control or cohort design was used and 2) studies contained available genotype frequencies. The major reasons for exclusion of studies were: no usable data were reported.

Data extraction and quality assessment
--------------------------------------

Two investigators independently extracted data and jointly reached a consensus on all of the studies researched. The following data were collected from each study: first author\'s name, publication year, original country, ethnicity, number of cases and controls, genotype frequencies for cases and controls, Hardy-Weinberg equilibrium (HWE) of controls and Newcastle-Ottawa Scale (NOS).[@B7] Star symbol was used to denote the quality, based on 3 aspects of the study: selection, comparability, and exposure. Studies with a score of 7 stars or greater were considered to be of high quality.

Statistical analysis
--------------------

The risks \[odds ratios (ORs), and 95% confidence intervals (95% CIs)\] of TB associated with *IL-10* and *IL-6* polymorphisms were estimated for each study based on extracted genotype data. The statistical significance of the pooled OR was determined using the Z-test. Heterogeneity assumption was examined by the Cochran\'s Q-test. If Q-test indicated *p*\<0.10, thus indicating a lack of heterogeneity among studies, then the fixed effect model was used (the Mantel-Haenszel method).[@B8] Otherwise, the random-effects model (the DerSimonian and Laird method)[@B9] was performed. Sensitivity analysis was mainly performed to assess the stability of the results, namely, a single study in the meta-analysis was deleted to reflect the influence of the individual data set on the pooled OR. Asymmetry funnel plots were inspected to assess potential publication bias. The Egger\'s linear regression test was also used to assess publication bias statistically. All the above statistical analyses were performed by using the software Stata Version 12.0 (Stata Corporation, College Station, TX, USA) and *p* values were two-tailed.

RESULTS
=======

Literature search and characteristics of eligible studies
---------------------------------------------------------

The flow chart that displays the study selection process is shown in [Fig. 1](#F1){ref-type="fig"}. The search of the selected databases retrieved 30 potentially relevant articles, including 7800 cases and 8793 controls, according to inclusion and exclusion criteria. There are 26 case-control studies concerning *IL-10* -1082G/A polymorphism,[@B6][@B10][@B11][@B12][@B13][@B14][@B15][@B16][@B17][@B18][@B19][@B20][@B21][@B22][@B23][@B24][@B25][@B26][@B27][@B29][@B30][@B31][@B32][@B33][@B34][@B35] 15 case-control studies for *IL-10* -819C/T polymorphism,[@B6][@B10][@B14][@B16][@B17][@B20][@B21][@B22][@B24][@B25][@B28][@B29][@B30][@B32][@B36] 16 case-control studies for *IL-10* -592A/C polymorphism,[@B6][@B10][@B14][@B15][@B16][@B17][@B20][@B21][@B24][@B25][@B26][@B29][@B30][@B32][@B33][@B36] and 7 case-control studies about *IL-6* -174G/C polymorphism. [@B6][@B16][@B17][@B21][@B25][@B37][@B38] Among the 30 eligible studies, 14 of them were of Asians,[@B6][@B11][@B15][@B18][@B19][@B21][@B22][@B23][@B28][@B30][@B31][@B35][@B37][@B38] 6 studies were of Europeans,[@B12][@B13][@B16][@B20][@B25][@B34] 6 studies were of Africans,[@B10][@B14][@B24][@B27][@B29][@B36] and 4 studies were of Americans.[@B17][@B26][@B32][@B33] The NOS scores ranged from 7 to 9, indicating that the methodological quality was generally good. The detailed characteristics of the eligible studies included in this meta-analysis are shown in [Table 1](#T1){ref-type="table"}, and the genotype and allele distributions of all four polymorphisms are shown in [Table 2](#T2){ref-type="table"}. The genotype distributions among the controls of all studies were consistent with the HWE except for eight studies for the *IL-10* -1082G/A,[@B6][@B11][@B13][@B23][@B25][@B27][@B29][@B34] one study for the *IL-10* -819C/T,[@B36] three studies for the *IL-10* -592A/C,[@B14][@B33][@B36] and two studies for the *IL-6* -174G/C ([Table 1](#T1){ref-type="table"}).[@B6][@B16]

Quantitative synthesis
----------------------

The summary of the meta-analysis for *IL-10* -1082G/A, -819C/T, -592A/C, and *IL-6* -174G/C polymorphisms and tuberculosis susceptibility is shown in [Table 3](#T3){ref-type="table"}.

Analysis of *IL-10* -1082G/A and TB susceptibility
--------------------------------------------------

In all, twenty-six studies consisted of 5949 cases and 6948 controls, and assessed the potential influence of the *IL-10* -1082G/A polymorphism with TB susceptibility. Random effects models were used to calculate the pooled OR in all genetic models. Overall, the combined results showed no significant association in all genetic models ([Fig. 2A-E](#F2){ref-type="fig"}). In the stratified analysis by ethnicity, *IL-10* -1082G/A polymorphism was associated with a significantly increased risk of TB in European group under recessive model (GG vs. AG+AA: OR=1.69, 95% CI=1.19-2.39). However, no significant association was found in American, Asian and African populations in all tested models. On subgroup analysis by sample types, significantly increased TB risk was observed under homozygous model (GG vs. AA: OR= 2.00, 95% CI=1.16-3.45) in PTB and extra-pulmonary tuberculosis (EPTB) mixed group. The results are shown in [Table 3](#T3){ref-type="table"}.

Analysis of *IL-10* -819C/T and TB susceptibility
-------------------------------------------------

As for *IL-10* -819C/T, there were fifteen studies involving 4207 cases and 5264 controls for data synthesis in our meta-analysis. The results showed that *IL-10* -819C/T polymorphism was not significantly associated with the risk of TB in all genetic models ([Fig. 2 F-J](#F2){ref-type="fig"}). In the stratified analyses by ethnicity and control source for the -819C/T polymorphism, a significantly increased risk was observed among Asians in heterozygous model and dominant model (TC vs. CC: OR=1.34, 95% CI=1.02-1.77; TT+TC vs. CC: OR=1.31, 95% CI=1.01-1.70). The results are shown in [Table 3](#T3){ref-type="table"}.

Analysis of *IL-10* -592A/C and TB susceptibility
-------------------------------------------------

In total, sixteen studies including 4115 cases and 5441 controls examined the relationship between the *IL-10* -592A/C polymorphism and TB susceptibility. As shown in [Table 3](#T3){ref-type="table"}, we failed to find the association between the *IL-10* -592A/C polymorphism and TB risk in all genetic models. In the stratified analyses for the *IL-10* -592A/C polymorphism, a significantly increased risk was observed among Asians in allele model (A allele vs. C allele: OR=1.26, 95% CI=1.08-1.28), homozygous model (AA vs. CC: OR=1.50, 95% CI=1.07-2.12), and recessive model (AA vs. AC+CC: OR=1.33, 95% CI=1.10-1.62) ([Table 3](#T3){ref-type="table"}).

Analysis of *IL-6* -174G/C and TB susceptibility
------------------------------------------------

A total of 1138 cases and 1311 controls from seven case-control studies were included for data synthesis. A decreased risk between *IL-6* -174G/C polymorphism and the risk of TB was observed in Allele model (C allele vs. G allele: OR=0.77, 95% CI=0.64-0.91), heterozygous model (CC vs. GG: OR=0.72, 95% CI=0.57-0.90), and dominant genetic model (CC+CG vs. GG: OR=0.71, 95% CI=0.57-0.88). In the stratified analysis by ethnicity, *IL-6* -174G/C polymorphism was associated with a significantly decreased risk of TB in Asian populations in Allele model (C allele vs. G allele: OR=0.71, 95% CI=0.54-0.93), heterozygous model (CC vs. GG: OR=0.61, 95% CI=0.44-0.85), and dominant genetic model (CC+CG vs. GG: OR=0.63, 95% CI=0.46-0.86). The results are shown in [Table 3](#T3){ref-type="table"}.

Heterogeneity analysis
----------------------

There were statistically significant heterogeneity in all genetic models for *IL-10* -1082G/A polymorphism, heterozygous model and dominant model for *IL-10* -819C/T polymorphism, and all genetic models except for heterozygous model for *IL-10* -592A/C ([Table 3](#T3){ref-type="table"}). To elucidate the heterogeneity, Galbraith plots were performed in these genetic models. When the studies which were outliers in some genetic models were excluded respectively, all I^2^ values were less than 50%, and *P*~heterogeneity~ were greater than 0.1 ([Fig. 3](#F3){ref-type="fig"}, [Table 4](#T4){ref-type="table"}). The significance of pooled OR in all genetic models was not influenced after excluding the studies. By meta-regression analysis, the heterogeneity sources were attributable to the sample types, ethnicity, control source, and the genotyping method. Ethnicity and sample types might be predominant sources of heterogeneity in *IL-10* -1082G/A polymorphism, and ethnicity and control source in both *IL-10* -819C/T and *IL-10* -592A/C polymorphisms ([Table 5](#T5){ref-type="table"}).

Sensitivity analysis
--------------------

Sensitivity analysis was performed by sequentially excluding individual studies, including studies which was not in agreement with HWE. Statistically similar results were obtained in all genetic models after sequentially excluding each study, indicating the stability of our data.

Publication bias
----------------

Begg\'s funnel plot and Egger\'s test were performed to assess the publication bias of included studies. The shapes of the funnel plots did not reveal any evidence of obvious asymmetry in the all genetic models. In all genetic models, Egger\'s test also did not show any significant statistical evidence of publication bias, indicating low risk of publication bias in this meta-analysis ([Fig. 4](#F4){ref-type="fig"}, [Table 6](#T6){ref-type="table"}).

DISCUSSION
==========

This is not the first meta-analysis to assess the associations between three polymorphisms (-1082G/A, -819C/T, and -592A/C) in the *IL-10* gene promoter and the risk of TB. We found that the results of our meta-analysis are inconsistent with a recent study of Liang, et al.[@B39] in which some following shortcomings were found : 1) the NOS scores of 3 Chinese articles included were lower than 7 stars through quality assessment, 2) two studies that meet the inclusion criterion were excluded (Ma, et al.,[@B28] Spinassé, et al.[@B32]), 3) the choice of genetic models was incorrect, 4) heterogeneity analysis and sensitivity analysis were missing, and 5) some extracted data was not accurate enough. Therefore, we performed this meta-analysis to examine the association between three *IL-10* and *IL-6* polymorphisms and TB risk again. Our meta-analysis results indicated that the presence of the *IL-10* -1082G/A, -819C/T, and -592A/C polymorphisms was not associated with the risk of TB in all genetic models. On the other hand, the *IL-6* -174G/C polymorphism might be associated with an decreased risk of TB in some genetic models (C allele vs. G allele: OR=0.77, 95% CI=0.64-0.91, *p*=0.003; CC vs. GG: OR=0.72, 95% CI=0.57-0.90, *p*=0.005; CC+CG vs. GG: OR=0.71, 95% CI=0.57-0.88, *p*=0.002).

We also carried out subgroup analysis based on ethnicity, sample types and control source in consideration of obvious heterogeneity. In the stratiied analysis by ethnicity, we observed significantly increased TB risk associated with the *IL-10* -1082G/A polymorphism in recessive model in Europeans, *IL-10* -819C/T polymorphism in Asians in heterozygous model and dominant model, *IL-10* -592A/C polymorphism in Asians in Allele model, homozygous model and recessive model respectively, and a decreased TB risk associated with *IL-6* -174G/C polymorphism was found in allele model, heterozygous model and dominant model in Asians. Different genetic background and environmental exposures might contribute to this ethnic difference. Subgroup analysis based on sample types suggested that *IL-10* -1082G/A polymorphism may be related with an increased risk of TB in homozygous model in the PTB+EPTB mixed sample. The results of subgroup analysis by control source revealed no signiicant association with TB susceptibility among *IL-10* and *IL-6* polymorphisms.

In our meta-analysis, obvious heterogeneity was observed for *IL-10* -1082G/A polymorphism in all genetic models, -819C/T polymorphism in heterozygous model and dominant model, and -592A/C polymorphism in all genetic models except for heterozygous model, whereas there was no obvious heterogeneity for *IL-6* -174G/C polymorphism. Then, we used the Galbraith plots to explore the sources of heterogeneity. We found that all the I^2^ values were less than 50% and *P*~heterogeneity~ were greater than 0.1 after excluding some studies, thus indicating that these studies might be the major source of the heterogeneity for the *IL-10* -1082G/A, -819C/T, and -592A/C polymorphisms. Owing to the limited number of studies in this meta-analysis, we restricted meta-regression analysis to four factors (sample types, ethnicity, control source, and genotyping method), which are the most likely to cause the heterogeneity between studies. Although the four above-mentioned factors had no significant impact on the heterogeneity except sample types factor for *IL-10* -1082G/A in homozygous model, the results of subgroup analyses revealed that the ethnicity and sample type might contribute to the potential heterogeneity.

Some limitations of this meta-analysis exist which should be considered when interpreting the present results. Firstly, heterogeneity is a potential problem when interpreting the results of meta-analysis. Significant heterogeneity existed among some comparisons, especially for *IL-10* -1082G/A and -592A/C polymorphisms. Secondly, this meta-analysis included the only published studies and publication bias may occur, although our results of publication bias showed no significance. Thirdly, host genetic susceptibility, environment factors and other factors might contribute to the pathogenesis of TB. Although many other factors such as age or gender may play a profound role in the development of TB, we did not make subgroup analysis based on these factors as data is not sufficient. Finally, some genetic polymorphisms of studies deviant from HWE were included in this meta-analysis, which suggested that there was potential bias during control selection or genotyping errors.

In conclusion, our meta-analysis suggested that *IL-10* -1082G/A, -819C/T, and -592A/C polymorphisms had no association with TB risk in general population, while the *IL-6* -174G/C polymorphism was signiicantly associated with decreased risk of TB in all genetic models except for recessive model. In the subgroup analysis, *IL-10* -1082G/A polymorphism was associated with TB risk in Europeans in recessive model, and *IL-10* -592A/C polymorphisms were significantly associated with TB risk in Asians in Allele model, homozygous model and recessive model, respectively, and a decreased TB risk associated with *IL-6* -174G/C polymorphism was found in allele model, heterozygous model and dominant model in Asians. Furthermore, *IL-10* -1082G/A polymorphism was associated also with an increased risk of TB in homozygous model in the PTB+EPTB mixed sample. However, additional well-designed and larger scale primary studies in populations with different ethnicities are required to further evaluate the *IL-10* and *IL-6* gene polymorphisms with TB risk in future.
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###### Baseline Characteristics of the 30 Eligible Studies Included in This Meta-Analysis

![](ymj-56-1274-i001)

  Study                             Yr     Male patients (%)   Mean age (yrs)                                                   Sample types                     Sample size   SNP studied   Clinical diagnoses performed   Control source               Sample tested                                                                      Genotyping method   NOS score   P-HWE for controls                  
  --------------------------------- ------ ------------------- ---------------------------------------------------------------- -------------------------------- ------------- ------------- ------------------------------ ---------------------------- ---------------------------------------------------------------------------------- ------------------- ----------- ------------------------------- --- ---------
  *IL-10*                                                                                                                                                                                                                                                                                                                                                                                                       
   Bellamy, et al.[@B10]            1998   67.4                34.7±13.2                                                        30.3±7.5                         PTB           401           408                            -1082G/A, -819C/T, -592A/C   Acidfast, bacilli (AFB)                                                            HB                  Blood       PCR-slot-blotting               7   0.824
   Delgado, et al.[@B11]            2002   37.3                42.2±14.1                                                        37.5±12.9                        PTB           356           106                            -1082G/A                     Sputum smear, medical history, physical examination                                HB                  Blood       RFLP-PCR                        9   \<0.001
   López-Maderuelo, et al.[@B12]    2003   NR                  NR                                                               NR                               PTB           113           100                            -1082G/A                     Culture, radiologic diagnosed                                                      HB                  Blood       ARMS-PCR                        8   0.949
   Scola, et al.[@B13]              2003   NR                  35-60                                                            NR                               PTB           45            114                            -1082G/A                     Clinical history, radiologic diagnosed                                             PB                  Blood       ARMS-PCR                        7   \<0.001
   Fitness, et al.[@B14]            2004   NR                  NR                                                               NR                               PTB           210           705                            -1082G/A, -819C/T, -592A/C   Culture, smear, history                                                            HB                  Blood       ARMS-PCR                        7   0.524
   Shin, et al.[@B15]               2005   NR                  46.9 (18-86)                                                     56.1 (50-81)                     PTB           450           851                            -1082G/A, -592A/C            AFB                                                                                HB                  Blood       Single-base extension methods   8   0.168
   Amirzargar, et al.[@B6]          2006   NR                  NR                                                               NR                               PTB           41            123                            -1082G/A, -819C/T, -592A/C   AFB, chest X-ray (CXR)                                                             HB                  Blood       PCR-SSP                         8   \<0.001
   Oral, et al.[@B16]               2006   NR                  NR                                                               NR                               PTB, EPTB     81            50                             -1082G/A, -819C/T, -592A/C   Staining of sputum smears, culture, biopsy, radiography                            HB                  Blood       PCR-SSP                         9   0.06
   Henao, et al.[@B17]              2006   57.9                15-70                                                            17-55                            PTB, EPTB     190           135                            -1082G/A, -819C/T, -592A/C   Ziehl-Nielssen staining of sputum smears, culture, biopsy, CXR, clinical history   HB                  Blood       PCR-SSP                         9   0.94
   Oh, et al.[@B18]                 2007   68.9                17-88                                                            45.8 (18-81)                     PTB           145           117                            -1082G/A                     Staining of sputum smears, culture, radiography                                    HB                  Blood       ARMS-PCR                        8   0.612
   Prabhu Anand, et al.[@B19]       2007   56.8                35.5±12.3                                                        29.7±9.5                         PTB           132           143                            -1082G/A                     Staining of sputum smears, culture, radiography                                    HB                  Blood       PCR-RFLP                        8   0.123
   Ates, et al.[@B20]               2008   62                  47.84±12.6                                                       54.1±7.2                         PTB, EPTB     128           80                             -1082G/A, -819C/T, -592A/C   Radiographic, clinical presentation, smears, culture                               HB                  Blood       ARMS-PCR                        9   0.978
   Selvaraj, et al.[@B21]           2008   71.7                Male: 35.3±10.5, female: 29.2±10.3                               Male: 32±8.1, female: 27.1±8.6   PTB           155           183                            -1082G/A, -819C/T,           Radiographic, clinical presentation, smears, culture                               PB                  Blood       PCR-RFLP                        7   0.204
   Wu, et al.[@B22]                 2008   NR                  NR                                                               NR                               PTB           61            122                            -1082G/A, -819C/T, -592A/C   Radiographic, clinical presentation, smears, culture                               HB                  Blood       PCR-RFLP                        7   0.379
   Ansari, et al.[@B23]             2009   NR                  NR                                                               NR                               PTB           188           188                            -1082G/A                     Microscopy, culture, histology, imaging                                            PB                  Blood       ARMS-PCR                        8   \<0.001
   Thye, et al.[@B24]               2009   NR                  NR                                                               NR                               PTB           2010          2346                           -1082G/A, -819C/T, -592A/C   Smears, culture                                                                    PB                  Blood       FRET                            8   0.542
   Trajkov, et al.[@B25]            2009   NR                  20-59                                                            NR                               PTB           75            299                            -1082G/A, -819C/T, -592A/C   WHO based                                                                          PB                  Blood       PCR-SSP                         7   \<0.001
   Taype, et al.[@B26]              2010   97.6                29.01±11.42                                                      32.56±9.39                       PTB, EPTB     626           513                            -1082G/A, -592A/C            Smears, culture, biopsy, clinical                                                  HB                  Blood       Taqman PCR                      9   0.142
  *IL-10*                                                                                                                                                                                                                                                                                                                                                                                                       
   Mosaad, et al.[@B27]             2010   67.3                0.5 (0.025-1.5)                                                  NR (0.047-1.5)                   PTB, EPTB     110           118                            -1082G/A                     Smear, culture                                                                     HB                  Blood       ARMS-PCR                        9   \<0.001
   Ma, et al.[@B28]                 2010   27.8                34.75±16.67                                                      38.17±17.39                      PTB           543           544                            -819C/T                      Radiographic, smears, culture                                                      HB                  Blood       ARMS-PCR                        9   0.491
   Ben-Selma, et al.[@B29]          2011   51.9                PTB: 44, EPTB: 39                                                35                               PTB, EPTB     131           95                             -1082G/A, -819C/T, -592A/C   Sputum smear, CXR, radiologic, histologic grounds                                  HB                  Blood       PCR-RFLP                        9   \<0.05
   Liang, et al.[@B30]              2011   NR                  NR                                                               NR                               PTB, EPTB     235           78                             -1082G/A, -819C/T, -592A/C   Radiographic, biopsy, clinical presentation, smears, culture                       HB                  Blood       SNaPshot assay                  9   0.589
   Ramaseri Sunder, et al.[@B31]    2012   NR                  NR                                                               NR                               PTB, EPTB     104           102                            -1082G/A                     Sputum smear, CXR, biopsy, Fine Needle Aspiration Cytology (FNAC)                  HB                  Blood       ARMS-PCR                        8   0.057
   Spinassé, et al.[@B32]           2012   NR                  NR                                                               NR                               PTB           221           271                            -1082G/A, -819C/T, -592A/C   Culture                                                                            HB                  Blood       Sequencing                      7   0.189
   García-Elorriaga, et al.[@B33]   2013   38.9                38-65                                                            26-41                            PTB           77            60                             -1082G/A, -592A/C            WHO based                                                                          HB                  Blood       Taqman PCR                      7   0.728
   Ulger, et al.[@B34]              2013   84.5                32.57±15.94                                                      29.40±11.56                      PTB, EPTB     84            110                            -1082G/A                     Smear, culture                                                                     HB                  Blood       PCR-RFLP                        8   \<0.001
   Meenakshi, et al.[@B35]          2013   50                  27.4±13.9                                                        30±10.7                          PTB           100           100                            -1082G/A                     Radiographic, sputum culture, AFB, histocytological examination                    HB                  Blood       ARMS-PCR                        8   0.058
   Mhmoud, et al.[@B36]             2013   69.6                36.9 (15-89)                                                     31.2 (17-85)                     PTB           191           206                            -819C/T, -592A/C             Culture, smear                                                                     HB                  Blood       PCR-RFLP                        8   \<0.001
  *IL-6*                                                                                                                                                                                                                                                                                                                                                                                                        
   Oral, et al.[@B16]               2006   NR                  NR                                                               NR                               PTB, EPTB     81            49                             -174G/C                      Staining of sputum smears, culture, biopsy, radiography                            HB                  Blood       PCR-SSP                         9   \<0.05
   Henao, et al.[@B17]              2006   57.9                15-70                                                            17-55                            PTB, EPTB     190           135                            -174G/C                      Ziehl-Nielssen staining of sputum smears, culture, biopsy, CXR, clinical history   HB                  Blood       PCR-SSP                         9   0.689
   Amirzargar, et al.[@B6]          2006   NR                  NR                                                               NR                               PTB           40            119                            -174G/C                      AFB, CXR                                                                           HB                  Blood       PCR-SSP                         8   \<0.05
   Selvaraj, et al.[@B21]           2008   71.7                Male: 35.3±10.5, female: 29.2±10.3                               Male: 32±8.1, female: 27.1±8.6   PTB           160           183                            -174G/C                      Radiographic, clinical presentation, smears, culture                               PB                  Blood       PCR-RFLP                        7   0.419
   Trajkov, et al.[@B25]            2009   NR                  20-59                                                            NR                               PTB           75            301                            -174G/C                      WHO based                                                                          PB                  Blood       PCR-SSP                         7   0.492
   Ansari, et al.[@B37]             2011   NR                  Minimal/moderate disease: 32.4±15.9; advanced disease: 27±17.0   28.3±12.1                        PTB           97            166                            -174G/C                      Radiographic, smears, culture                                                      PB                  Blood       ARMS-PCR                        8   0.567
   Zhang, et al.[@B38]              2012   62                  38.64±18.44                                                      36.92±16.52                      PTB           495           358                            -174G/C                      Radiographic, smears, culture                                                      HB                  Blood       Mass spectrometry               8   0.979

NR, not report; PTB, pulmonary tuberculosis; EPTB, extra-pulmonary tuberculosis; SNP, single nucleotide polymorphism; PB, population-based controls; HB, hospital-based controls; PCR, polymerase chain reaction; SSP, sequence-specific primers; ARMS, amplification refractory mutation system; RFLP, restriction fragment length polymorphism; NOS, newcastle-ottawa scale; C, confirmed to HWE; HWE, Hardy-Weinberg equilibrium.

###### Genotype and Allele Distributions of *IL-10* and *IL-6* Polymorphisms in Cases and Controls

![](ymj-56-1274-i002)

  Polymorphisms     Study                            Country     Ethnicity   Case   Control   Case   Control                                      
  ----------------- -------------------------------- ----------- ----------- ------ --------- ------ --------- ----- ------ ------- ------ ------ ------
  *IL-10*-1082G/A   Bellamy, et al.[@B10]            Gambia      African     51     185       165    45        184   179    287     515    274    542
                    Delgado, et al.[@B11]            Cambodia    Asian       11     259       86     3         64    39     281     431    70     142
                    López-Maderuelo, et al.[@B12]    Spain       European    33     47        33     29        50    21     113     113    108    92
                    Scola, et al.[@B13]              Italy       European    17     22        6      24        77    13     56      34     125    103
                    Fitness, et al.[@B14]            Malawi      African     23     78        69     87        251   203    124     216    425    657
                    Shin, et al.[@B15]               Korea       Asian       2      53        394    9         124   718    57      841    142    1560
                    Amirzargar, et al.[@B6]          Iran        Asian       2      31        7      5         79    18     35      45     89     115
                    Oral, et al.[@B16]               Turkey      European    10     41        30     5         13    32     61      101    23     77
                    Henao, et al.[@B17]              Colombia    American    32     92        66     26        66    43     156     224    118    152
                    Oh, et al.[@B18]                 Korea       Asian       4      43        98     19        53    45     51      239    91     143
                    Prabhu, et al.[@B19]             India       Asian       3      55        74     6         61    73     61      203    73     207
                    Ates, et al.[@B20]               Turkey      European    26     65        37     6         32    42     117     139    44     116
                    Selvaraj, et al.[@B21]           India       Asian       5      42        102    6         69    108    52      246    81     285
                    Wu, et al.[@B22]                 China       Asian       1      12        48     0         18    104    14      108    18     226
                    Ansari, et al.[@B23]             Pakistan    Asian       27     132       29     20        136   32     186     190    176    200
                    Thye, et al.[@B24]               Ghana       African     117    631       793    160       783   1025   865     2217   1103   2833
                    Trajkov, et al.[@B25]            Macedonia   European    10     48        17     17        212   70     68      82     246    352
                    Taype, et al.[@B26]              Peru        American    22     187       414    10        153   347    231     1015   173    847
                    Mosaad, et al.[@B27]             Egypt       African     16     92        2      22        88    8      124     96     132    104
                    Ben-Selma, et al.[@B29]          Tunisian    African     21     65        45     9         26    60     168.8   155    44     146
                    Liang, et al.[@B30]              China       Asian       0      28        207    0         9     69     28      442    9      147
                    Ramaseri Sunder, et al.[@B31]    India       Asian       3      25        76     2         43    57     31      177    47     157
                    Spinassé, et al.[@B32]           Brazil      American    24     100       97     31        107   133    148     294    169    373
                    García-Elorriaga, et al.[@B33]   Mexico      American    54     20        3      31        25    4      128     26     87     33
                    Ulger, et al.[@B34]              Turkey      European    0      84        0      1         104   5      84      84     106    114
                    Meenakshi, et al.[@B35]          India       Asian       4      81        15     16        59    25     89      111    91     109

  Polymorphisms    Study                     Country     Ethnicity   Case   Control   Case   Control                                    
  ---------------- ------------------------- ----------- ----------- ------ --------- ------ --------- ----- ----- ------ ------ ------ ------
  *IL-10*-819C/T   Bellamy, et al.[@B10]     Gambia      African     89     192       120    88        206   114   370    432    382    434
                   Fitness, et al.[@B14]     Malawi      African     27     98        85     108       303   287   152    268    519    877
                   Amirzargar, et al.[@B6]   Iran        Asian       2      20        19     9         52    62    24     58     70     176
                   Oral, et al.[@B16]        Turkey      European    10     23        48     7         19    24    43     119    33     67
                   Henao, et al.[@B17]       Colombia    American    32     92        66     21        64    50    156    224    106    164
                   Ates, et al.[@B20]        Turkey      European    7      58        63     8         36    36    72     184    52     108
                   Selvaraj, et al.[@B21]    India       Asian       45     86        24     56        82    45    176    134    194    172
                   Wu, et al.[@B22]          China       Asian       24     34        3      50        62    10    82     40     162    82
                   Thye, et al.[@B24]        Ghana       African     267    762       515    365       942   665   1296   1792   1672   2272
                   Trajkov, et al.[@B25]     Macedonia   European    5      35        35     19        125   155   45     105    163    435
                   Ma, et al.[@B28]          China       Asian       229    256       58     230       253   61    714    372    713    375
                   Ben-Selma, et al.[@B29]   Tunisian    African     11     65        55     10        42    43    87     175    62     128
                   Liang, et al.[@B30]       China       Asian       123    90        22     35        31    12    336    134    101    55
                   Spinassé, et al.[@B32]    Brazil      American    32     100       89     38        124   109   164    278    200    342
                   Mhmoud, et al.[@B36]      Sudan       African     42     126       23     70        73    63    210    172    213    199

  Polymorphisms    Study                     Country   Ethnicity   Case   Control   Case   Control                                  
  ---------------- ------------------------- --------- ----------- ------ --------- ------ --------- ----- ----- ----- ----- ------ -----
  *IL-10*-592A/C   Bellamy, et al.[@B10]     Gambia    African     89     192       120    88        206   114   370   432   382    434
                   Fitness, et al.[@B14]     Malawi    African     27     98        85     107       301   297   152   268   515    895
                   Shin, et al.[@B15]        Korea     Asian       238    173       39     376       384   91    649   251   1136   566
                   Amirzargar, et al.[@B6]   Iran      Asian       2      20        18     9         52    62    24    56    70     176

  Polymorphisms   Study                            Country     Ethnicity   Case   Control   Case   Control                                   
  --------------- -------------------------------- ----------- ----------- ------ --------- ------ --------- ----- ----- ----- ------ ------ ------
                  Oral, et al.[@B16]               Turkey      European    10     23        48     7         19    24    43    119    33     67
                  Henao, et al.[@B17]              Colombia    American    72     89        29     41        67    27    233   147    149    121
                  Ates, et al.[@B20]               Turkey      European    7      58        63     8         36    36    72    184    52     108
                  Wu, et al.[@B22]                 China       Asian       24     34        3      50        62    10    82    40     162    82
                  Thye, et al.[@B24]               Ghana       African     172    532       321    269       696   480   876   1174   1234   1656
                  Trajkov, et al.[@B25]            Macedonia   European    5      31        39     28        117   154   41    109    173    425
                  Taype, et al.[@B26]              Peru        American    117    218       264    105       230   178   452   746    440    586
                  Ben-selma, et al.[@B29]          Tunisian    African     12     63        56     10        42    43    87    175    62     128
                  Liang, et al.[@B30]              China       Asian       123    90        22     35        31    12    336   134    101    55
                  Spinassé, et al.[@B32]           Brazil      American    34     102       85     37        127   107   170   272    201    341
                  García-elorriaga, et al.[@B33]   Mexico      American    1      57        19     1         42    17    59    95     44     76
                  Mhmoud, et al.[@B36]             Sudan       African     127    47        17     100       68    38    301   81     268    144

  Polymorphisms   Study                     Country     Ethnicity   Case   Control   Case   Control                                
  --------------- ------------------------- ----------- ----------- ------ --------- ------ --------- ----- ----- ---- ----- ----- -----
  *IL-6*-174G/C   Oral, et al.[@B16]        Turkey      European    6      27        48     9         13    27    39   123   31    67
                  Henao, et al.[@B17]       Colombia    American    11     73        106    13        61    61    95   285   87    183
                  Amirzargar, et al.[@B6]   Iran        Asian       4      13        23     10        71    38    21   59    91    147
                  Selvaraj, et al.[@B21]    India       Asian       3      35        122    3         51    129   41   279   57    309
                  Trajkov, et al.[@B25]     Macedonia   European    8      31        36     25        132   144   47   103   182   420
                  Ansari, et al.[@B37]      Pakistan    Asian       4      24        69     10        56    100   32   162   76    256
                  Zhang, et al.[@B38]       China       Asian       0      4         491    0         1     357   4    986   1     715

*IL-10*, interleukin 10; *IL-6*, interleukin 6.

###### Determination of the Genetic Effects of *IL-10* and *IL-6* Polymorphisms on TB and Subgroup Analysis

![](ymj-56-1274-i003)

                    Allele model            Homozygous model   Heterozygous model   Dominant model   Recessive model                                                                
  ----------------- ----------------------- ------------------ -------------------- ---------------- -------------------- ------- -------------------- ------- -------------------- -------
  *IL-10*-1082G/A   G allele vs. A allele   GG vs. AA          AG vs. AA            GG+AG vs. AA     GG vs. AG+AA                                                                   
   Ethnicity                                                                                                                                                                        
    Overall         1.05(0.93,1.19)         0.423              1.15(0.87,1.51)      0.320            1.08(0.90,1.29)      0.393   1.09(0.91,1.31)      0.335   1.09(0.87,1.38)      0.448
    European        1.34(1.00,1.80)         0.054              1.88(0.93,3.80)      0.079            1.35(0.70,2.63)      0.369   1.49(0.79,2.79)      0.215   F1.69(1.19, 2.39)    0.003
    American        F1.10(0.95,1.27)        0.201              F1.16(0.81,1.67)     0.421            F1.07 (0.88,1.30)    0.509   F1.09 (0.90,1,31)    0.372   F1.23 (0.90,1.68)    0.203
    Asian           0.85(0.67,1.09)         0.209              0.69(0.36,1.36)      0.285            0.91(0.66,1.26)      0.940   0.89(0.63,1.25)      0.494   0.67(0.36,1.26)      0.212
    African         1.12(0.91,1.38)         0.289              1.20(0.81,1.77)      0.369            1.32(0.93,1.87)      0.126   1.31 (0.92,1.88)     0.131   F0.97 (0.81,1.17)    0.761
   Sample types                                                                                                                                                                     
    PTB             0.98(0.85,1.12)         0.726              0.93(0.70,1.25)      0.646            0.97(0.81,1.15)      0.691   0.96(0.80,1.15)      0.651   1.01 (0.76,1.34)     0.958
    PTB+EPTB        1.23(0.94,1.62)         0.130              2.00(1.16,3.45)      0.013            1.53(0.95,2.49)      0.084   1.56(0.97,2.52)      0.067   1.31 (0.89,1.93)     0.176
  *IL-10*-819C/T    T allele vs. C allele   TT vs. CC          TC vs. CC            TT+TC vs. CC     TT vs. TC+CC                                                                   
   Ethnicity                                                                                                                                                                        
    Overall         F1.01 (0.95,1.07)       0.788              F1.01 (0.89,1.15)    0.834            1.21(1.00,1.46)      0.056   1.14(0.98,1.34)      0.099   F0.93 (0.84,1.03)    0.164
    European        F0.92(0.71,1.19)        0.512              F0.75 (0.40,1.42)    0.380            F0.97 (0.68,1.37)    0.846   0.93(0.67,1.30)      0.678   F0.79 (0.43,1.44)    0.438
    American        F1.04 (0.85,1.27)       0.732              F1.08(0.71,1.65)     0.721            F1.03 (0.76,1.39)    0.870   F1.04 (0.78,1.38)    0.799   F1.06 (0.72,1.57)    0.756
    Asian           F1.08 (0.95,1.23)       0.265              F1.24 (0.92,1.67)    0.157            F1.34 (1.02,1.77)    0.035   F1.31 (1.01,1.70)    0.043   F1.01 (0.84,1.22)    0.897
    African         F0.99 (0.92,1.07)       0.812              F0.97 (0.83, 1.13)   0.691            1.34(0.90,2.00)      0.148   1.21 (0.89,1.64)     0.231   F0.88 (0.77,1.01)    0.065
   Control source                                                                                                                                                                   
    HB              F1.01 (0.93,1.10)       0.785              F1.04 (0.87,1.24)    0.685            1.20(0.92,1.55)      0.175   1.13(0.92,1.39)      0.237   F0.93 (0.81,1.07)    0.310
    PB              F1.01(0.92,1.09)        0.919              F0.99 (0.82,1.19)    0.908            1.26(0.89,1.78)      0.201   1.20(0.88,1.64)      0.258   F0.92 (0.79, 0.84)   0.339
  *IL-10*-592A/C    A allele vs. C allele   AA vs. CC          AC vs. CC            AA+AC vs. CC     AA vs. AC+CC                                                                   
   Ethnicity                                                                                                                                                                        
    Overall         1.07(0.95,1.19)         0.270              1.09(0.89,1.33)      0.401            F1.01 (0.91, 1.12)   0.839   1.06(0.91,1.22)      0.474   1.09(0.93,1.29)      0.291
    European        F0.84 (0.65,1.09)       0.181              F0.64 (0.35,1.18)    0.153            F0.90(0.63,1.27)     0.536   F0.85 (0.61,1.18)    0.323   F0.68 (0.38,1.23)    0.204
    American        1.01(0.80,1.28)         0.918              F0.93 (0.72,1.20)    0.595            0.91(0.64,1.31)      0.623   0.97(0.67,1.39)      0.859   F1.07 (0.86,1.34)    0.545
    Asian           F1.26 (1.08,1.45)       0.002              F1.50 (1.07, 2.12)   0.020            F1.21 (0.88,1.67)    0.250   F1.35 (0.99,1.83)    0.058   F1.33 (1.10,1.62)    0.004
    African         1.12(0.91,1.37)         0.290              1.12(0.79,1.58)      0.528            F1.11(0.97,1.27)     0.144   F1.09 (0.96,1.24)    0.175   1.08(0.77,1.52)      0.654
   Control source                                                                                                                                                                   
    HB              1.08(0.94,1.24)         0.254              1.14(0.90,1.45)      0.289            F0.95(0.84,1.08)     0.429   1.07(0.89,1.29)      0.464   1.15(0.97,1.37)      0.111
    PB              1.00(0.89,1.1 1)        0.933              0.94(0.75,1.19)      0.607            F1.13(0.95,1.34)     0.154   1.08(0.91,1.22)      0.359   0.87(0.71,1.07)      0.194
  *IL-6*-174G/C     C allele vs. G allele   CC vs. GG          CG vs. GG            CC+CG vs. GG     CC vs. CG+GG                                                                   
   Overall          F0.77 (0.64, 0.91)      0.003              F0.67 (0.43,1.05)    0.078            F0.72(0.57, 0.90)    0.005   F0.71 (0.57, 0.88)   0.002   F0.77 (0.50,1.19)    0.243
   European         F0.92 (0.67,1.26)       0.594              0.73(0.22,2.43)      0.610            F1.00(0.64,1.57)     0.987   F0.94 (0.62,1.42)    0.773   0.72(0.20,2.59)      0.615
   Asian            F0.71 (0.54,0.93)       0.013              F0.69 (0.32,1.48)    0.343            F0.61 (0.44,0.85)    0.004   F0.63 (0.46, 0.86)   0.004   F0.93 (0.44,1.97)    0.855

TB, tuberculosis; PTB, pulmonary tuberculosis; EPTB, extra-pulmonary tuberculosis; PB, population-based controls; HB, hospital-based controls; R, random effect model; F, fixed effect model; *IL-10*, interleukin 10; *IL-6*, interleukin 6; CI, confidence interval; OR, odds ratio.

###### Meta-Analyses of *IL-10* Polymorphisms and Risk of TB after Omitting the Studies

![](ymj-56-1274-i004)

  Polymorphisms     Omitted studies                                                                                                                                                    OR (95% CI)         Z      *P*~OR~   I^2^ (%)   *P*~heterogeneity~   Effect model
  ----------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------- ------ --------- ---------- -------------------- --------------
  *IL-10*-1082G/A                                                                                                                                                                                                                                           
   G vs. A          Ates, et al.;[@B20] García-Elorriaga, et al.;[@B33] Oh, et al.;[@B18] Ramaseri Sunder, et al.;[@B31] Wu, et al.[@B22]                                              1.02 (0.96, 1.09)   0.69   0.488     9.4        0.336                F
   GG vs. AA        Ates, et al.;[@B20] Ramaseri Sunder, et al.;[@B31] Wu, et al.[@B22]                                                                                                1.04 (0.90, 1.21)   0.54   0.588     2.2        0.430                F
   AG vs. AA        Ansari, et al.;[@B37] Ates, et al.;[@B20] García-Elorriaga, et al.;[@B33] Oh, et al.;[@B18] Ramaseri Sunder, et al.;[@B31] Scola, et al.;[@B13] Wu, et al.[@B22]   1.00 (0.92, 1.09)   0.01   0.989     0.0        0.486                F
   GG+AG vs. AA     Ates, et al.;[@B20] García-Elorriaga, et al.;[@B33] Oh, et al.;[@B18] Ramaseri Sunder, et al.;[@B31] Scola, et al.;[@B13] Wu, et al.[@B22]                         1.01 (0.93, 1.10)   0.25   0.802     11.6       0.311                F
   GG vs. AG+AA     Ansari, et al.;[@B37] Ates, et al.;[@B20] Meenakshi, et al.;[@B35] Mosaad, et al.;[@B27] Wu, et al.[@B22]                                                          1.03 (0.90, 1.19)   0.46   0.645     0.0        0.623                F
  *IL-10*-819C/T                                                                                                                                                                                                                                            
   TC vs. CC        Zhang, et al.[@B38]                                                                                                                                                1.06 (0.96, 1.17)   1.19   0.234     0.0        0.671                F
   TT+TC vs. CC     Zhang, et al.[@B38]                                                                                                                                                1.04 (0.95, 1.14)   0.80   0.424     0.0        0.683                F
  *IL-10*-592A/C                                                                                                                                                                                                                                            
   A vs. C          Ma, et al.;[@B28] Taype, et al.;[@B26] Zhang, et al.[@B38]                                                                                                         1.08 (0.99, 1.17)   1.78   0.075     3.7        0.409                F
   AA vs. CC        Zhang, et al.[@B38]                                                                                                                                                0.99 (0.87, 1.13)   0.11   0.913     5.9        0.386                F
   AA+AC vs. CC     Zhang, et al.[@B38]                                                                                                                                                1.00 (0.91, 1.10)   0.08   0.936     29.1       0.138                F
   AA vs. AC+CC     Henao, et al.;[@B17] Zhang, et al.[@B38]                                                                                                                           0.96 (0.85, 1.09)   0.63   0.526     0.0        0.845                F

TB, tuberculosis; CI, confidence interval; OR, odds ratio; *Pheterogeneity*, *p* value of Q test for heterogeneity; F, fixed-effect models; *IL-10*, interleukin 10.

###### Multivariate Meta-Regression Analyses of Potential Source of Heterogeneity

![](ymj-56-1274-i005)

  Heterogeneity factors                       Coefficient                             SE                                  t                                  *p* value                           95% CI                                   
  ------------------------------------------- --------------------------------------- ----------------------------------- ---------------------------------- ----------------------------------- ---------------------------------------- -----------------------------------
  Sample types                                                                                                                                                                                                                            
   *IL*-*10*-1082G/A (AM, HoM, HeM, DM, RM)   0.234, 0.924, 0.407, 0.433, 0.457       0.183, 0.361, 0.278, 0.279, 0.289   1.28, 2.56, 1.46, 1.55, 1.58       0.215, 0.019, 0.158, 0.136, 0.130   -0.146, 0.170, -0.171, -0.148, -0.146    0.614, 1.679, 0.985, 1.014, 1.061
   *IL-10*-819C/T (HeM, DM)                   -0.119, -0.071                          0.345, 0.285                        -0.35, -0.25                       0.737, 0.808                        -0.887, -0.706                           0.649, 0.564
   *IL-10*-592A/C (AM, HoM, DM, RM)           -0.091, -0.104, -0.162, -0.055          0.158, 0.316, 0.203, 0.235          -0.57, -0.33, -0.80, -0.23         0.577, 0.748, 0.440, 0.819          -0.438, -0.800, -0.609, -0.572           0.256, 0.592, 0.284, 0.462
  Ethnicity                                                                                                                                                                                                                               
   *IL-10*-1082G/A (AM, HoM, HeM, DM, RM)     -0.082, -0.118, 0.014, -0.031, -0.223   0.077, 0.141, 0.124, 0.124, 0.108   -1.07, -0.83, 0.11, -0.25, -2.06   0.298, 0.415, 0.910, 0.804, 0.052   -0.241, -0.413, -0.244, -0.290, -0.448   0.077, 0.177, 0.272, 0.227, 0.002
   *IL-10*-819C/T (HeM, DM)                   0.116, 0.082                            0.141, 0.115                        0.82, 0.71                         0.433, 0.493                        -0.120, -0.175                           0.431, 0.339
   *IL-10*-592A/C (AM, HoM, DM, RM)           0.067, 0.106, 0.084, 0.062              0.067, 0.137, 0.082, 0.110          1.00, 0.78, 1.02, 0.57             0.339, 0.453, 0.329, 0.583          -0.081, -0.195, -0.097, -0.179           0.215, 0,407, 0.264, 0.304
  Control source                                                                                                                                                                                                                          
   *IL-10*-1082G/A (AM, HoM, HeM, DM, RM)     0.093, 0.528, -0.137, -0.057, 0.545     0.207, 0.366, 0.308, 0.311, 0.295   0.45, 1.44, -0.44, -0.18, 1.85     0.659, 0.166, 0.661, 0.855, 0.080   -0.338, -0.239, -0.776, -0.705, -0.070   0.524, 1.295, 0.503, 0.590, 1.161
   *IL-10*-819C/T (HeM, DM)                   0.053, 0.051                            0.363, 0.294                        0.14, 0.17                         0.888, 0.867                        -0.757, -0.605                           0.862, 0.707
   *IL-10*-592A/C (AM, HoM, DM, RM)           -0.157, -0.368, -0.090, -0.395          0.191, 0.362, 0.225, 0.265          -0.82, -1.02, -0.40, -1.49         0.429, 0.331, 0.697, 0.165          -0.577, -1.165, -0.585, -0.978           0.263, 0.429, 0.405, 0.189
  Genotyping method                                                                                                                                                                                                                       
   *IL-10*-1082G/A (AM, HoM, HeM, DM, RM)     0.075, 0.124, 0.051, 0.068, 0.137       0.064, 0.121, 0.098, 0.099, 0.095   1.17, 1.02, 0.52, 0.69, 1.44       0.254, 0.319, 0.606, 0.499, 0.164   -0.058, -0.129, -0.152, -0.137, -0.061   0.209, 0.376, 0.254, 0.273, 0.335
   *IL-10*-819C/T (HeM, DM)                   0.006, 0.022                            0.131, 0.106                        0.05, 0.21                         0.965, 0.840                        -0.285, -0.214                           0.297, 0.257
   *IL-10*-592A/C (AM, HoM, DM, RM)           0.015, 0.074, -0.024, 0.090             0.060, 0.117, 0.073, 0.089          0.24, 0.63, -0.32, 1.01            0.813, 0.538, 0.752, 0.336          -0.118, -0.183, -0.185, -0.107           0.147, 0.331, 0.137, 0.286

SE, standard error; CI, confidence interval; UL, upper limit; LL, lower limit; AM, allele model; HoM, homozygous model; HeM, heterozygous model; DM, dominant model; RM, recessive model; *IL-10*, interleukin 10.

###### Publication Bias of *IL-10* -1082G/A, *IL-10* -819C/T, and *IL-10* -592A/C Polymorphisms in all Genetic Models

![](ymj-56-1274-i006)

  Polymorphisms                              Z~Begg\'s~                     P~Begg\'s~                          t~Egger\'s~                     P~Egger\'s~
  ------------------------------------------ ------------------------------ ----------------------------------- ------------------------------- -----------------------------------
  *IL*-*10*-1082G/A (AM, HoM, HeM, DM, RM)   0.93, 0.47, 1.01, 1.28, 0.35   0.355, 0.637, 0.311, 0.201, 0.726   0.60, 0.79, 0.82, 0.95, 0.21    0.555, 0.436, 0.418, 0.352. 0.839
  *IL*-*10*-819C/T (AM, HoM, HeM, DM, RM)    0.99, 0.10, 1.88, 1.78, 0.99   0.322, 0.921, 0.060, 0.075, 0.322   1.04, 0.80, 1.30, 1.28, -0.68   0.317, 0.438, 0.217, 0.221, 0.511
  *IL*-*10*-592A/C (AM, HoM, HeM, DM, RM)    0.23, 0.32, 1.22, 1.31, 0.59   0.822, 0.753, 0.224, 0.192, 0.558   0.59, 0.57, 0.90, 1.36, -0.68   0.564, 0.575, 0.385, 0.195, 0.505
  *IL*-*6*-174G/C (AM, HoM, HeM, DM, RM)     0.30, 0.75, 0.90, 0.00, 0.38   0.764, 0.452, 0.368, 1.000, 0.707   0.57, -0.09, 0.57, 0.51, 0.07   0.596, 0.934, 0.592, 0.634, 0.945

AM, allele model; HoM, homozygous model; HeM, heterozygous model; DM, dominant model; RM, recessive model; *IL-10*, interleukin 10; *IL-6*, interleukin 6.
